Zhendong Chen

3.7k total citations · 1 hit paper
54 papers, 1.0k citations indexed

About

Zhendong Chen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Zhendong Chen has authored 54 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Zhendong Chen's work include Cancer Immunotherapy and Biomarkers (15 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Colorectal Cancer Treatments and Studies (9 papers). Zhendong Chen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Colorectal Cancer Treatments and Studies (9 papers). Zhendong Chen collaborates with scholars based in China, United States and Taiwan. Zhendong Chen's co-authors include Yuxian Bai, Shukui Qin, Zhenggang Ren, Zhiqiang Meng, Jianjun Zou, Xiaohong Chen, Weijia Fang, Jianping Xiong, Linna Wang and Mengjie Fang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Zhendong Chen

51 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

2022 127 citations Shukui Qin, Zhendong Chen et al. Journal of Clinical Oncology profile →

Peers

Zhendong Chen

ONCOL

PRM

HEPAT

RNMI

SURGE

Diana L. Hanna United States

Feng Han China

Steven Blotner United States

Bin‐Yan Zhong China

Cyril Hatem France

Takahiro Einama Japan

Maobin Meng China

Boris Galjart Netherlands

J. Tol Netherlands

E. Cohen United States

Diana L. Hanna United States

Zhendong Chen

600 ×1.2

ONCOL

250 ×0.7

PRM

117 ×0.4

HEPAT

122 ×0.6

RNMI

164 ×1.1

SURGE

Citations per year, relative to Zhendong Chen Zhendong Chen (= 1×) peers Diana L. Hanna

Countries citing papers authored by Zhendong Chen

Since Specialization

Citations

This map shows the geographic impact of Zhendong Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhendong Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhendong Chen more than expected).

Fields of papers citing papers by Zhendong Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhendong Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhendong Chen. The network helps show where Zhendong Chen may publish in the future.

Co-authorship network of co-authors of Zhendong Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Zhendong Chen. A scholar is included among the top collaborators of Zhendong Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhendong Chen. Zhendong Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xu, Binghe, Qingyuan Zhang, Yang Luo, et al.. (2025). Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial. Nature Communications. 16(1). 716–716. 2 indexed citations

Chan, Stephen L., Zhenggang Ren, Yuxian Bai, et al.. (2024). Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.. Journal of Clinical Oncology. 42(16_suppl). 4110–4110. 16 indexed citations

Chen, Zhendong, Xingyun Su, Weipu Zhu, et al.. (2024). Preoperative Serum Lipids as Novel Predictors of Survival in 3575 Patients With Papillary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 110(3). 668–676. 2 indexed citations

Li, Jiaqi, et al.. (2024). Latent relation shared learning for endometrial cancer diagnosis with incomplete multi-modality medical images. iScience. 27(8). 110509–110509. 1 indexed citations

Chen, Likun, Timuçin Çil, İrfan Çiçin, et al.. (2023). Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study. Cancer Medicine. 12(22). 20847–20863. 3 indexed citations

Yu, Yang, Ya Li, & Zhendong Chen. (2023). Impact of low serum iron on treatment outcome of PD-1 inhibitors in advanced gastric cancer. BMC Cancer. 23(1). 1095–1095.

Chen, Zhendong, et al.. (2023). Identification of immune-related genes and patient selection for hepatocellular carcinoma immunotherapy. Translational Cancer Research. 12(5). 1210–1231. 1 indexed citations

Wang, Jiayu, Qingyuan Zhang, Tao Sun, et al.. (2023). A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 1072–1072. 1 indexed citations

Qin, Shukui, Zhendong Chen, Weijia Fang, et al.. (2022). Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology. 41(7). 1434–1443. 127 indexed citations breakdown →

10.

Fang, Jie & Zhendong Chen. (2022). Evaluation of Short‐Term Efficacy of PD‐1 Monoclonal Antibody Immunotherapy for Lymphoma by Positron Emission Tomography/Computed Tomography Imaging with Convolutional Neural Network Image Registration Algorithm. Contrast Media & Molecular Imaging. 2022(1). 1388517–1388517. 3 indexed citations

11.

Qin, Shukui, Shanzhi Gu, Zhenggang Ren, et al.. (2021). Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. International Journal of Cancer. 149(11). 1944–1954. 38 indexed citations

12.

Chen, Shanshan, Yiqun Han, Quchang Ouyang, et al.. (2021). Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy. BMC Cancer. 21(1). 341–341. 4 indexed citations

13.

Wang, Weibin, Xingyun Su, Yongfeng Ding, et al.. (2021). Thyroid Function Abnormalities in COVID-19 Patients. Frontiers in Endocrinology. 11. 623792–623792. 61 indexed citations

14.

Li, Jin, Yuxian Bai, Qingshan Li, et al.. (2021). CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology. 39(3_suppl). TPS255–TPS255. 2 indexed citations

15.

Lin, Yansong, Hui Yang, Yong Ding, et al.. (2020). Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial. Thyroid. 31(4). 607–615. 32 indexed citations

16.

Yuan, Peng, Xichun Hu, Tao Sun, et al.. (2019). Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. European Journal of Cancer. 112. 57–65. 68 indexed citations

17.

Chen, Zhendong, et al.. (2019). Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer. Journal of Cancer Research and Therapeutics. 15(2). 365–365. 8 indexed citations

18.

Han, Xuan, Gan Chen, Zhonglian Huang, et al.. (2017). Altered network efficiency of functional brain networks in patients with breast cancer after chemotherapy. Oncotarget. 8(62). 105648–105661. 20 indexed citations

19.

Chen, Zhendong, et al.. (2012). Proteomic analysis of neutrophils of rats with Acinetobacter baumannii sepsis. Zhonghua weishengwuxue he mianyixue zazhi. 32(5). 385–394. 2 indexed citations

20.

Zhang, Mingjun, T. Sun, Zhonglian Huang, et al.. (2011). A comparative study: Diffusion weighted whole body imaging with background body signal suppression and hybrid Positron Emission Computed Tomography on detecting lesions in oncologic clinics. European Journal of Radiology. 81(7). 1662–1666. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact